Article
Gastroenterology & Hepatology
Manasi Agrawal, Erica J. Brenner, Xian Zhang, Jean-Frederic Colombel, Michael D. Kappelman, Ryan C. Ungaro, Richard B. Gearry, Gilaad G. Kalpan, Michele Kissous-Hunt, James D. Lewis, Siew C. Ng, Jean-Francois Rahier, Walter Reinisch, Frank M. Ruemmele, Flavio Steinwurz, Fox E. Underwood
Summary: More than one third of IBD patients stopped medication due to COVID-19, with those diagnosed with ulcerative colitis or IBD-unspecified less likely to stop compared to Crohn's disease patients. Specific medications such as 5-aminosalicylic acid were more likely to be continued, while anti-tumour necrosis factor therapy and immunomodulator therapy were more likely to be stopped. Other demographic and clinical characteristics did not impact prescription patterns.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Immunology
Lev Lichtenstein, Benjamin Koslowsky, Ami Ben Ya'acov, Irit Avni-Biron, Baruch Ovadia, Ofer Ben-Bassat, Timna Naftali, Uri Kopylov, Yael Haberman, Hagar Eran, Rami Eliakim, Adi Lahat-Zok, Ayal Hirsch, Eran Zittan, Nitsan Maharshak, Matti Waterman, Eran Israeli, Idan Goren, Jacob Ollech, Henit Yanai, Bella Ungar, Benjamin Avidan, Dana Ben Hur, Bernardo Melamud, Ori Segol, Zippora Shalem, Iris Dotan, Selwyn Odes, Shomron Ben-Horin, Yf'at Snir, Yael Milgrom, Efrat Broide, Eran Goldin, Shmuel Delgado, Yulia Ron, Nathaniel Cohen, Eran Maoz, Maya Zborovsky, Safwat Odeh, Naim Abu Freha, Eyal Shachar, Yehuda Chowers, Tal Engel, Hila Reiss-Mintz, Arie Segal, Adar Zinger, Ariella Bar-Gil Shitrit
Summary: The use of immunosuppressive therapy in IBD patients does not worsen the severity of COVID-19, and in fact, patients receiving biologics have milder infection course. Treatment can be postponed until recovery from COVID-19.
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Jose Maria Huguet, Luis Ferrer-Barcelo, Patricia Suarez, Eva Sanchez, Jose David Prieto, Victor Garcia, Javier Sempere
Summary: The detection of dysplasia in IBD patients is important and chromoendoscopy with targeted biopsy remains the preferred technique. However, other techniques such as virtual chromoendoscopy are being compared due to their similar results and fewer technical difficulties. New endoscopy techniques and improved devices have the potential to revolutionize the screening and follow-up of dysplasia in IBD patients. Further research is needed to define the optimal follow-up strategy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Raffi Lev-Tzion, Gili Focht, Rona Lujan, Adi Mendelovici, Chagit Friss, Shira Greenfeld, Revital Kariv, Amir Ben-Tov, Eran Matz, Daniel Nevo, Yuval Barak-Corren, Iris Dotan, Dan Turner
Summary: COVID-19 vaccine effectiveness in IBD patients is comparable to non-IBD controls and is not affected by treatment with TNF inhibitors or corticosteroids. The risk of IBD exacerbation did not differ between vaccinated and unvaccinated patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Medicine, General & Internal
Byron P. Vaughn
Summary: Therapeutic drug monitoring (TDM) is a useful strategy for optimizing biologic medications for inflammatory bowel disease, but the focus on serum drug concentration may limit its effectiveness. Physicians need to consider drug concentration in conjunction with inflammatory status and understand the limitations of TDM when making therapeutic decisions with imperfect information.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Mohammed Deputy, Kapil Sahnan, Guy Worley, Komal Patel, Violeta Balinskaite, Alex Bottle, Paul Aylin, Elaine M. Burns, Ailsa Hart, Omar Faiz
Summary: The Covid-19 pandemic has had a detrimental effect on inflammatory bowel disease (IBD) services, leading to delays in emergency care and access to investigations and surgeries. A study in England found significant decreases in hospital attendances for acute ulcerative colitis (UC) and acute Crohn's disease (CD), as well as a decrease in the volume of IBD procedures and investigations. The study also highlighted the importance of prioritizing care for patients with IBD to prevent clinical harm and a decrease in quality of life.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Medicine, General & Internal
Yu Nishida, Shuhei Hosomi, Koji Fujimoto, Rieko Nakata, Naoko Sugita, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Satoko Ohfuji, Yasuhiro Fujiwara
Summary: The study found that 34% of UC patients and 46% of CD patients reported disease exacerbation within 2 months after the lockdown. For UC, age, sleep duration, and stress due to the COVID-19 pandemic were independent factors associated with exacerbation. For CD, age and active disease before the state of emergency were independently associated with exacerbation.
FRONTIERS IN MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Chiara Vigano, Giacomo Mulinacci, Andrea Palermo, Donatella Barisani, Lorena Pirola, Maria Fichera, Pietro Invernizzi, Sara Massironi
Summary: Patients with inflammatory bowel diseases (IBD) are not at increased risk of contracting severe acute respiratory syndrome coronavirus 2 infection. However, advanced age, comorbidities, and treatment with high-dose corticosteroids have been identified as risk factors for severe COVID-19 course in IBD patients.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Medicine, General & Internal
Aleksandra Kubas, Ewa Malecka-Wojciesko
Summary: Vaccination against COVID-19 is considered safe and effective for patients with IBD, although further research is needed to understand its safety in special populations. The willingness to receive the vaccine among IBD patients is conflicting, with concerns about effectiveness and safety being the most common reasons for hesitancy.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, Research & Experimental
Chunxiu Yang, Shu-Yuan Xiao
Summary: COVID-19, caused by SARS-CoV-2, can lead to severe complications such as multiple organ failure, with most patients also experiencing gastrointestinal symptoms. Managing these symptoms presents challenges for patients with inflammatory bowel disease (IBD) due to potential interactions between the immune response to COVID-19 and dysregulated immunity associated with IBD.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Gastroenterology & Hepatology
Natalia S. F. Queiroz, Camilla de Almeida Martins, Abel B. Quaresma, Adriano A. F. Hino, Flavio Steinwurz, Ryan C. Ungaro, Paulo G. Kotze
Summary: In Latin America, IBD patients diagnosed with COVID-19 have similar outcomes to global data, with risk factors for severe COVID-19 being similar to previous reports.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Pediatrics
Katherine F. Sweeny, Yanjia J. Zhang, Bonnie Crume, Colin A. Martz, Melissa M. Blessing, Stacy A. Kahn
Summary: The case describes a 16-year-old boy with MIS-C and severe inflammatory bowel disease. Treatment with a combination of steroids, intravenous immunoglobulin, and infliximab led to symptom resolution over a 3-week period. Emphasizing the need to investigate the impact of COVID-19 and MIS-C on inflammatory disorders.
Review
Immunology
Francesco Paolo Bianchi, Rossella Donghia, Rossella Tatoli, Caterina Bonfiglio
Summary: This study assessed the global coverage of COVID-19 vaccination among individuals with IBD through a comprehensive meta-analysis and systematic review. The findings showed suboptimal vaccination rates among this population. Factors such as ethnicity, gender, immunosuppressive therapy, age, prior vaccine experience, history of infection, and advice from gastroenterologists were associated with vaccination uptake.
Review
Microbiology
Gian Mario Cortes, Maria Antonietta Marcialis, Flaminia Bardanzellu, Angelica Corrias, Vassilios Fanos, Michele Mussap
Summary: This study compared the metabolic and microbial changes in patients with inflammatory bowel diseases (IBD) and coronavirus disease 2019 (COVID-19). Both diseases are characterized by gut dysbiosis, intestinal barrier breakdown, and alterations in microbial and metabolic pathways. The dysbiosis is marked by the prevalence of pro-inflammatory bacteria and a decrease in anti-inflammatory species.
FRONTIERS IN MICROBIOLOGY
(2022)
